AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AstraZeneca is conducting a Phase III study titled ‘A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)’. The study aims to evaluate the efficacy of a triple therapy inhaler on cardiopulmonary outcomes in patients with COPD at elevated risk, highlighting its potential significance in improving treatment options for this population.
Intervention/Treatment: The study tests two inhalation therapies: BGF MDI, a combination of budesonide, glycopyrronium, and formoterol fumarate, and GFF MDI, comprising glycopyrronium and formoterol fumarate. These treatments aim to improve cardiopulmonary outcomes in COPD patients.
Study Design: This is a randomized, double-blind, parallel group study, meaning participants are randomly assigned to one of the two treatment groups without knowing which they receive. The study involves multiple centers and is primarily focused on treatment efficacy.
Study Timeline: The study began on February 21, 2024, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on August 20, 2025, indicating ongoing recruitment and progress.
Market Implications: This study could significantly impact AstraZeneca’s stock performance and investor sentiment, as positive results may enhance the company’s COPD treatment portfolio. Competitors in the respiratory treatment market may face increased pressure to innovate or adjust strategies in response to these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.